Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Agenus (AGEN) to $8 from $11 and keeps a Buy rating on the shares. The firm ...

The company is seeking to convert the vaccine’s emergency use authorization received in 2022 into a full approval that would ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $69 and keeps a Buy rating on the shares following ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart (VXRT) to $2 from $2.50 and keeps a Buy rating on the shares. The Q4 update reaffirmed the mid-2025 top-line data ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full approval, sending the drugmaker's shares soaring and easing concerns around the ...

Appreciate all the comments, guys. Operator: The next question is from the line of Mayank Mamtani with B. Riley Securities. Please proceed with your questions. Mayank Mamtani: Yes, good morning team.

The investment bank has a $109 price target (~111% upside based on Nov. 21 close). Analyst Mayank Mamtani said that VK2735 could set itself apart from existing weight loss drugs as it is a "GLP1 ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Cassava Sciences (NASDAQ:SAVA) on Tuesday, setting a price... Investing.com – U.S. stocks were lower after the close on Friday ...